BPC-157 and TB-500 Together: What One Study Found

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

Until recently, writing about these two peptides together meant reasoning from their separate literatures, because no study had tested them side by side. That changed. A 2026 study in Joint Diseases and Related Surgery compared BPC-157, synthetic thymosin beta-4 and their combination in one rat model — and the combination result is not what the usual rationale predicts.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

The study design

Element	Detail
Model	Rat Achilles tendon transection and repair
Groups	Control, BPC-157, TB-500, combination
Animals	32 total, eight per group
Duration	Four weeks post-operative
Biomechanical readout	Maximum load to failure
Histological scoring	Bonar and Movin systems
Histochemistry	Haematoxylin-eosin, Masson trichrome, Alcian blue, Sirius red
Immunohistochemistry	Collagen types I and III, H-score

The design is worth noting for what it includes: a four-arm structure with a genuine combination group, a mechanical endpoint alongside histology, and multiple staining methods rather than one. That is more rigorous than most published work on either peptide individually.

What the combination arm showed

The authors’ statement is direct: combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone. They discuss the absence of additive effects as possibly reflecting convergence on shared pathways.

This matters because the rationale usually offered for combining the two is complementarity — the suggestion that each contributes something the other does not. The single study that tested that proposition directly did not find it. Anyone evaluating the combination should know this, and it is the reason we are writing about it plainly rather than omitting it.

The interpretation the authors offer is mechanistically reasonable. If two agents act on overlapping pathways, combining them produces a ceiling rather than a sum. That is a standard pharmacological outcome and not evidence against either agent individually.

The individual arms

On the reported measures the two agents did not perform identically:

Maximum load to failure was higher in both treatment groups than control, reaching statistical significance in the TB-500 group.
Bonar scores were significantly lower in the TB-500 group.
Movin scores were significantly lower in the TB-500 and combination groups.
The BPC-157 group showed numerically lower scores without reaching significance on total scores.
Collagen type I expression did not differ significantly between groups; type III expression did.

With eight animals per group, a numerical trend that does not reach significance is an underpowered result rather than a negative one. The authors describe the study as exploratory, and that framing should be carried through to any conclusion drawn from it.

What one study can and cannot establish

Can establish	Cannot establish
That the combination was tested and no additivity was observed	That additivity never occurs, in any tissue or timeframe
Direction and rough size of effects in this model	Relative potency with confidence at n=8
That a four-arm design is feasible	Outcomes at other timepoints than four weeks
A mechanistic hypothesis worth testing	Whether pathway convergence is the actual explanation

The honest summary is that the only direct evidence on the combination does not support an additive rationale, and that this evidence is a single exploratory study. Both halves of that sentence are load-bearing.

The separate literatures, briefly

BPC-157’s own evidence base is the larger of the two and has an unusual strength: the 2022 study by He and colleagues characterised its pharmacokinetics, distribution, metabolism and excretion in rats and dogs, which is rare for a research peptide. Mechanistically, the 2017 study by Hsieh and colleagues associated its pro-angiogenic activity with VEGFR2 activation rather than identifying a receptor.

Two recent reviews frame the human picture. The 2025 narrative review by McGuire and colleagues is titled “Regeneration or Risk?” — a framing that signals unsettled evidence — and the 2026 systematic review by Poolton and colleagues assesses human evidence in orthopaedic and regenerative medicine. The compound-level detail is in what BPC-157 is and BPC-157 compared with TB-500.

Practical notes for a blend

If the two are used together regardless, two handling points apply:

Prepare and verify separately where possible. A pre-mixed preparation cannot be checked arm by arm, and if a result is anomalous there is no way to tell which component was at fault.
Molar amounts, not mass amounts. The two peptides differ in molecular weight, so a blend specified by mass is not specified by molarity. Our reconstitution calculator works from net peptide mass and molecular weight for each component.

Our BPC-157 and TB-500 blend research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report.

Scope note

This material is supplied for laboratory research use only. It is not a medicine, not a supplement, and not for human or veterinary use. The study reviewed above was conducted in rats; nothing here describes administration to any organism.

Open questions

Does the absence of additivity hold in tissues other than tendon?
Would a larger study detect a difference between the individual arms?
Is pathway convergence the explanation, or is it a ceiling effect of the model?

Frequently asked questions

Is there any published research on the two peptides together?

Yes, and it is recent. A 2026 study in Joint Diseases and Related Surgery tested BPC-157, synthetic thymosin beta-4 and their combination in a rat Achilles tendon transection and repair model, with biomechanical, histopathological, histochemical and immunohistochemical readouts.

What did the combination arm show?

The authors reported that combined treatment did not confer additional benefits compared to either agent alone. They discussed the absence of additive effects as possibly reflecting convergence on shared pathways.

Which agent performed better in that study?

Synthetic thymosin beta-4 reached statistical significance on more measures, including maximum load to failure and the histopathological scores. The BPC-157 arm showed numerically lower scores without reaching significance on total scores.

Does one study settle the question?

No. It is a single exploratory animal study in one tissue with eight animals per group, and the authors describe it as exploratory. It is, however, the only direct test of the combination available, which makes it more informative than inference from the separate literatures.

Why does this matter for a blend product?

Because the rationale usually offered for combining them is that their effects add or complement each other. The one study that tested this directly did not find additivity, and anyone considering the combination should know that rather than assume the opposite.

References

Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PMID: 42542926 https://pubmed.ncbi.nlm.nih.gov/42542926/
He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. PMID: 36588717 https://pubmed.ncbi.nlm.nih.gov/36588717/
Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017. PMID: 27847966 https://pubmed.ncbi.nlm.nih.gov/27847966/
McGuire FP, et al. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. PMID: 40789979 https://pubmed.ncbi.nlm.nih.gov/40789979/
Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg. 2026. PMID: 42885452 https://pubmed.ncbi.nlm.nih.gov/42885452/